Abstract
Six-hundred patients were recruited between 1986 and 1991 for studies of the treatment of Ph positive chronic myeloid leukemia (CML) with interferon-alpha (IFN-alpha). The median survival of the patients who were assigned to treatment with IFN-alpha was 6 years or longer than 6 years, and was more than the survival of the patients who were assigned to conventional chemotherapy. Survival prolongation was significantly related with the achievement of a cytogenetic response. IFN-alpha treatment was not harmful for subsequent allogeneic or autologous bone marrow transplantation.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / therapeutic use*
-
Bone Marrow Transplantation
-
Clinical Protocols
-
Combined Modality Therapy
-
Humans
-
Hydroxyurea / therapeutic use
-
Interferon alpha-2
-
Interferon-alpha / therapeutic use*
-
Italy / epidemiology
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
-
Middle Aged
-
Prospective Studies
-
Recombinant Proteins
-
Survival Rate
Substances
-
Antineoplastic Agents
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Hydroxyurea